Side-by-side · Research reference

FOXO4-DRIvsGonadorelin

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongHUMAN-REVIEWED12/45 cited

BFDA-ApprovedHUMAN-REVIEWED7/61 cited

FOXO4-DRI

Senolytic Peptide · D-Retro-Inverso

p53-TADMolecular targetBourgeois 2025

Pre-clinicalDevelopment stage

SQRoute (animal)

SQ · Animal models only

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

01Mechanism of Action

Parameter

FOXO4-DRI

Gonadorelin

Primary target

FOXO4-p53 protein complex in senescent cellsBourgeois 2025 Tripathi 2021

GnRH receptors on anterior pituitary gonadotropes

Pathway

FOXO4-DRI binds disordered p53 transactivation domain → displaces FOXO4 → nuclear p53 exclusion → p53-mediated apoptosis in senescent cells

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

Downstream effect

Selective apoptosis of senescent cells; clearance restores tissue homeostasisTripathi 2021 Alameen 2026

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Feedback intact?

—

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

Origin

D-retro-inverso modification — inverted amino acid sequence, D-amino acids for protease resistance

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Antibody development

—

02Dosage Protocols

Parameter

FOXO4-DRI

Gonadorelin

Animal dose (mouse)

5 mg/kg

SQ injection, aged mouse model (testosterone restoration).

—

Frequency (animal)

Variable — single or intermittent dosing

Protocol-dependent; no standardised regimen.

—

Human equivalent (theoretical)

~0.4 mg/kg (28 mg / 70 kg adult)

Extrapolated using allometric scaling; no clinical validation.

—

Evidence basis

Animal / mechanistic

RCT / Expert consensus

Route

SQ (animal)

No human route established.

IV preferred (therapeutic) · SQ acceptable (diagnostic)

Duration

Weeks to months (animal studies)

Senescent cell clearance observed within weeks.

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

Clinical status

No human trials completed

—

Diagnostic test (pituitary function)

—

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

Therapeutic (hypothalamic hypogonadism)

—

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

Pulsatile interval

—

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

Half-life

—

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

Alternative protocols

—

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

03Metabolic / Fat Loss Evidence

Parameter

FOXO4-DRI

Gonadorelin

Fat loss mechanism

—

None — gonadorelin acts exclusively on reproductive axis

Indirect metabolic effects

—

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

04Side Effects & Safety

Parameter

FOXO4-DRI

Gonadorelin

Pulmonary hypertension risk

Senescent cell elimination promoted PH development/progression in rodent modelsBorn 2023

—

Context-dependent toxicity

Beneficial effects may be tissue/context-specific; elimination not universally protectiveBorn 2023

—

Off-target apoptosis

Theoretical risk of non-senescent cell apoptosis (selectivity not absolute)

—

Immune perturbation

Senescent cells contribute to immune surveillance; clearance effects unknown

—

Human safety unknown

No clinical trials — toxicity profile in humans not established

—

Injection site reaction

—

Erythema, irritation (pulsatile pump catheter site)

Headache

—

Common with bolus administration

Nausea / abdominal discomfort

—

Transient, dose-related

Ovarian hyperstimulation syndrome (OHSS)

—

Risk with ovulation induction protocols; monitor follicular development via ultrasound

Multiple gestation

—

Increased risk with fertility protocols (twins ~10–15%)

Anaphylaxis

—

Rare hypersensitivity reaction

Pump malfunction / infection

—

Mechanical failure or catheter-site infection with long-term IV pump use

Receptor desensitization

—

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

Absolute Contraindications

FOXO4-DRI

·Pulmonary hypertension or vascular disease (preclinical evidence of harm)Born 2023
·Pregnancy / lactation (no safety data)

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Relative Contraindications

FOXO4-DRI

·Active malignancy (senescence as tumour suppressor mechanism)
·Wound healing / tissue repair (senescent cells involved in fibrosis resolution)

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

05Administration Protocol

Parameter

FOXO4-DRI

Gonadorelin

1. Pre-clinical route

Subcutaneous injection used in rodent models. No human administration protocol exists.

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

2. Reconstitution (animal)

Typically reconstituted in sterile saline or PBS for animal experiments. Stability data limited.

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

3. Dosing schedule

Variable — single bolus or intermittent dosing over weeks. No standardised human protocol.

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

4. Clinical development status

No registered human trials. Commercialisation by Cleara Biotech (Netherlands) in development phase.

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

5. Safety monitoring (proposed)

Would require cardiovascular assessment, pulmonary function, immune panel, tumour surveillance if human trials proceed.

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

06Stack Synergy

FOXO4-DRI

— no documented stacks

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function